Jump to ContentJump to Main Navigation
Show Summary Details
More options …

Journal of Pediatric Endocrinology and Metabolism

Editor-in-Chief: Kiess, Wieland

Ed. by Bereket, Abdullah / Darendeliler, Feyza / Dattani, Mehul / Gustafsson, Jan / Luo, Fei Hong / Mericq, Veronica / Ogata, Tsutomu / Toppari, Jorma

12 Issues per year


IMPACT FACTOR 2017: 1.086

CiteScore 2017: 1.07

SCImago Journal Rank (SJR) 2017: 0.465
Source Normalized Impact per Paper (SNIP) 2017: 0.580

Online
ISSN
2191-0251
See all formats and pricing
More options …
Volume 30, Issue 4

Issues

Growth-hormone deficiency in mitochondrial disorders

Josef Finsterer / Marlies Frank
Published Online: 2017-01-13 | DOI: https://doi.org/10.1515/jpem-2016-0418

References

  • 1.

    Quintos JB, Hodax JK, Gonzales-Ellis BA, Phornphutkul C, Wajnrajch MP, et al. Efficacy of growth hormone therapy in Kearns-Sayre syndrome: the KIGS experience. J Pediatr Endocrinol Metab 2016;29:1319–24.Google Scholar

  • 2.

    Kang YX, Wang YJ, Zhang Q, Pang XH, Gu W. A case of hypopituitarism accompanying Kearns-Sayre syndrome treated with human chorionic gonadotropin: a case report and literature review. Andrologia 2016. doi: .CrossrefGoogle Scholar

  • 3.

    Berio A, Piazzi A. Multiple endocrinopathies (growth hormone deficiency, autoimmune hypothyroidism and diabetes mellitus) in Kearns-Sayre syndrome. Pediatr Med Chir 2013;35:137–40.Google Scholar

  • 4.

    Obara-Moszynska M, Maceluch J, Bobkowski W, Baszko A, Jaremba O, et al. A novel mitochondrial DNA deletion in a patient with Kearns-Sayre syndrome: a late-onset of the fatal cardiac conduction deficit and cardiomyopathy accompanying long-term rGH treatment. BMC Pediatr 2013;13:27.Google Scholar

  • 5.

    Holloman CM, Wolfe LA, Gahl WA, Boerkoel CF. Kearns-Sayre syndrome presenting as isolated growth failure. BMJ Case Rep 2013;2013. pii: bcr2012007272.Google Scholar

  • 6.

    Berio A, Piazzi A. Facial anomalies in a patient with cytochrome-oxidase deficiency and subsequent Kearns-Sayre syndrome with growth hormone deficiency. Minerva Med 2007;98:81–5.Google Scholar

  • 7.

    De Sanctis V, Calzolari F, Piazzi A, Berio A. Kearns-Sayre syndrome associated with growth hormone deficiency. Pediatr Med Chir 2003;25:447–51.Google Scholar

  • 8.

    Berio A, Piazzi A. Kearns-Sayre syndrome with GH deficiency. Pediatr Med Chir 2000;22:43–6.Google Scholar

  • 9.

    Mohri I, Taniike M, Fujimura H, Matsuoka T, Inui K, et al. A case of Kearns-Sayre syndrome showing a constant proportion of deleted mitochondrial DNA in blood cells during 6 years of follow-up. J Neurol Sci 1998;158:106–9.Google Scholar

  • 10.

    Eviatar L, Shanske S, Gauthier B, Abrams C, Maytal J, et al. Kearns-Sayre syndrome presenting as renal tubular acidosis. Neurology 1990;40:1761–3.Google Scholar

  • 11.

    Burns EC, Preece MA, Cameron N, Tanner JM. Growth hormone deficiency in mitochondrial cytopathy. Acta Paediatr Scand 1982;71:693–7.Google Scholar

  • 12.

    Egger J, Kendall BE. Computed tomography in mitochondrial cytopathy. Neuroradiology 1981;22:73–8.Google Scholar

  • 13.

    O’Grady MJ, Monavari AA, Cotter M, Murphy NP. Sideroblastic anaemia and primary adrenal insufficiency due to a mitochondrial respiratory chain disorder in the absence of mtDNA deletion. BMJ Case Rep 2015;2015. pii: bcr2014208514.Google Scholar

  • 14.

    Schwartzentruber J, Buhas D, Majewski J, Sasarman F, Papillon-Cavanagh S, et al. Mutation in the nuclear-encoded mitochondrial isoleucyl-tRNA synthetase IARS2 in patients with cataracts, growth hormone deficiency with short stature, partial sensorineural deafness, and peripheral neuropathy or with Leigh syndrome. Hum Mutat 2014;35:1285–9.Google Scholar

  • 15.

    Romano S, Samara D, Crosnier H, Valayannopoulos V, Polak M, et al. Variable outcome of growth hormone administration in respiratory chain deficiency. Mol Genet Metab 2008;93:195–9.Google Scholar

  • 16.

    Cassandrini D, Savasta S, Bozzola M, Tessa A, Pedemonte M, et al. Mitochondrial DNA deletion in a child with mitochondrial encephalomyopathy, growth hormone deficiency, and hypoparathyroidism. J Child Neurol 2006;21:983–5.Google Scholar

  • 17.

    Saneto RP, Bouldin A. A boy with muscle weakness, hypercarbia, and the mitochondrial DNA A3243G mutation. J Child Neurol 2006;21:77–9.Google Scholar

  • 18.

    Barberi S, Bozzola E, Berardinelli A, Meazza C, Bozzola M. Long-term growth hormone therapy in mitochondrial cytopathy. Horm Res 2004;62:103–6.Google Scholar

  • 19.

    Matsuzaki M, Izumi T, Shishikura K, Suzuki H, Hirayama Y. Hypothalamic growth hormone deficiency and supplementary GH therapy in two patients with mitochondrial myopathy, encephalopathy, lactic acidosis and stroke-like episodes. Neuropediatrics 2002;33:271–3.Google Scholar

  • 20.

    Balestri P, Grosso S. Endocrine disorders in two sisters affected by MELAS syndrome. J Child Neurol 2000;15:755–8.Google Scholar

  • 21.

    Gücüyener K, Seyrantepe V, Topaloğlu H, Ozgüç M. Mitochondrial deletion in a boy with growth hormone deficiency mimicking cerebral palsy. J Inherit Metab Dis 1998;21:173–4.Google Scholar

  • 22.

    Yorifuji T, Kawai M, Momoi T, Sasaki H, Furusho K, et al. Nephropathy and growth hormone deficiency in a patient with mitochondrial tRNA(Leu(UUR)) mutation. J Med Genet 1996;33:621–2.Google Scholar

  • 23.

    Niaudet P, Heidet L, Munnich A, Schmitz J, Bouissou F, et al. Deletion of the mitochondrial DNA in a case of de Toni-Debré-Fanconi syndrome and Pearson syndrome. Pediatr Nephrol 1994;8:164–8.Google Scholar

  • 24.

    Yang CY, Lam HC, Lee HC, Wei YH, Lu CC, et al. MELAS syndrome associated with diabetes mellitus and hyperthyroidism: a case report from Taiwan. Clin Endocrinol (Oxf) 1995;43:235–9.Google Scholar

  • 25.

    Chen XY, Zhao SY, Wang Y, Wang D, Dong CH, et al. A novel mitochondrial DNA deletion in a patient with Pearson syndrome and neonatal diabetes mellitus provides insight into disease etiology, severity and progression. Mitochondrial DNA A DNA Mapp Seq Anal 2016;27:2492–5.Google Scholar

About the article

Corresponding author: Josef Finsterer, MD, PhD, Krankenanstalt Rudolfstiftung, Postfach 20, 1180 Vienna, Austria, Europe, Phone: +43-1-71165-92085, Fax: +43-1-4781711


Received: 2016-11-05

Accepted: 2016-11-11

Published Online: 2017-01-13

Published in Print: 2017-04-01


Author contributions: All the authors have accepted responsibility for the entire content of this submitted manuscript and approved submission.

Research funding: None declared.

Employment or leadership: None declared.

Honorarium: None declared.

Competing interests: The funding organization(s) played no role in the study design; in the collection, analysis, and interpretation of data; in the writing of the report; or in the decision to submit the report for publication.


Citation Information: Journal of Pediatric Endocrinology and Metabolism, Volume 30, Issue 4, Pages 479–481, ISSN (Online) 2191-0251, ISSN (Print) 0334-018X, DOI: https://doi.org/10.1515/jpem-2016-0418.

Export Citation

©2017 Walter de Gruyter GmbH, Berlin/Boston.Get Permission

Comments (0)

Please log in or register to comment.
Log in